Bionano Genomics, Inc. (BNGO)
Market Cap | 59.62M |
Revenue (ttm) | 36.12M |
Net Income (ttm) | -232.49M |
Shares Out | 54.69M |
EPS (ttm) | -6.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,702,959 |
Open | 1.100 |
Previous Close | 1.090 |
Day's Range | 1.090 - 1.170 |
52-Week Range | 1.000 - 11.800 |
Beta | 2.37 |
Analysts | Buy |
Price Target | 8.00 (+620.72%) |
Earnings Date | Mar 5, 2024 |
About BNGO
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearizatio... [Read more]
Financial Performance
In 2023, BNGO's revenue was $36.12 million, an increase of 29.90% compared to the previous year's $27.80 million. Losses were -$232.49 million, 75.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 620.72% from the latest price.
News
Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Including Live Product Showcase Featuring the Company's New Stratys™ System
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Ge...
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2023 and revenue outlook fo...
Bionano to Present at TD Cowen's 44th Annual Health Care Conference
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at TD Cowen's 4...
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern ...
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (“Bionano”) (Nasdaq: BNGO) today announced that is has amended the convertible debt financing the company entered into in October 20...
Bionano to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science & Diagnostic Tools Conference
SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will participate in the BTIG...
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the second interim report from an ongoing clinical trial designed to support estab...
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
SAN DIEGO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the full commercial release of the Stratys™ system, the Company's system for high throughput optical ...
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (Nasdaq: BNGO) today announced its 2024 Symposium lineup of 33 oral presentations delivered by 26 different customers worldwide featu...
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. The even...
Bionano Reports Preliminary Fourth Quarter and Full-Year 2023 Results
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial and commercial highlights for the fourth quarter and fiscal ye...
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first framework paper...
OGM Added to International System for Human Cytogenomic Nomenclature
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of optical genome mapping (OGM) to the International System for...
Bionano Announces Significant Upgrades to its Bionano Solve Pipeline and its VIA™ Software for OGM Data Analysis in Constitutional Genetic Disease Research
SAN DIEGO, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced significant upgrades to its pipeline for analysis of optical genome mapping (OGM) data in its VIA™ s...
Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping
Key findings from prospective evaluation of 200 prenatal samples: Optical genome mapping (OGM) detected pathogenic structural variants (SVs) in 20.5% of samples (41/200); combination of chromosomal mi...
Cancers Journal Publishes Special Issue Dedicated to OGM's Impact on Hematological Malignancy Research
SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of a special issue of Cancers journal entirely dedicated to the Company's optical ge...
Study Shows that OGM Plays an Important Role in Efficient Diagnosis of FSHD
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bom...
Bionano Announces Publication Demonstrating Utility of OGM to Assess Genome Integrity of CRISPR-Edited Cells as Part of Gene Therapy Development
SAN DIEGO, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication demonstrating the use of optical genome mapping (OGM) to identify structural variations...
Bionano Announces Presentation of OGM Utility Across Key Research Applications at the Association for Molecular Pathology Annual Meeting
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo with ...
Bionano Reports Third Quarter 2023 Results and Highlights Recent Business Progress
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2023.
Bionano to Report Third Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 8, 2023
SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, November 8, 2023, at 4:30 p.m. Eas...
Bionano Prices $80.0 Million Financing in Convertible Notes and Warrants, Announces Preliminary Q3 2023 Results, and Implements Streamlined Operational Plan
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain business updates and unaudited preliminary financial results for the third quarter ended Septe...
Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease Analysis
SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM...
Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company's Board of Directors (the “Com...